Introduction
Superwarfarins are chemically modified forms of warfarin with up to 100 times greater potency than warfarin, and they are used primarily as rodenticides. Brodifacoum (BDF) is one of the most commonly used superwarfarins in the USA [1] . The main pathogenic mechanism of BDF action is similar to warfarin, namely a reduction of bioavailable vitamin K resulting in excessive anticoagulation
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Since its introduction as a rodenticide in the late 1980s, there have been increasing numbers of patients with accidental or intentional BDF ingestion. Such cases are occurring at a rate of more than 10,000 individuals per year, mostly in children under the age of 6 years, with a mortality rate of about 20% [7, 8] . In addition, due to its easy availability, there is a concern that BDF could be used as a chemical weapon in terrorist attacks [5] . Currently, there are no early biomarkers to identify BDF ingestion; patients typically present to a medical facility with already severe anticoagulation. Availability of a biomarker will help in rapid identification of poisoned patients, initiate treatment and reduce the number of casualties. We previously demonstrated that BDF results in acute kidney injury in animals with chronic kidney disease, but not in controls [9] . Uncontrolled BDF treatment was associated with hematuria, which developed 2-3 days after poisoning and was more significant in rats with chronic kidney disease than in controls [9] . These BDF renal effects were associated with its anticoagulation properties and were similar to the effects of warfarin on the kidney in humans and rats [9] [10] [11] . Accordingly, the aim of this study was to investigate renal effects of BDF administered in a controlled dose in rats and to determine whether BDF poisoning is associated with early renal damage that can be detected rapidly and non-invasively by first responders before coagulopathy is manifested.
Material and Methods

Animals
All experiments were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee. Adult male Sprague Dawley rats (180-220 g, Harlan Laboratories, Indianapolis, Ind., USA) were provided with food and water ad libitum.
Treatment with BDF and Antioxidant BDF (Sigma-Aldrich, St. Louis, Mo., USA) was dissolved at a concentration of 2 mg/ml in 100% methanol, then diluted at 1: 1 ratio with 100% ethanol, giving a final concentration of fully dissolved 1 mg/ml BDF. The stock solution was aliquoted and kept at -20 ° C until use. For oral gavage, the BDF stock solution was dissolved in distilled water to achieve the desired dosage; the total volume for gavage was 0.6 ml per animal.
The antioxidant N-acetylcysteine (NAC; Sigma-Aldrich, St. Louis, Mo., USA) was given per os in drinking water in the concentrations described below. Daily water consumption was measured, and daily NAC dosage was calculated from the animal weight.
Urinalysis
Free-catch urine was collected. Urinalysis was performed using DiaScreen (Chronimed Inc., Minnetonka, Minn., USA) reagent strips (dipstick) in the urine [9, 11] . Hematuria was graded using a semi-quantitative scale of 0-3+. Score 0 was designated for negative hematuria, score 1+ for mild hematuria, score 2+ for moderate hematuria and score 3+ for severe hematuria.
Analyses of Blood Samples
Blood (approximately 150 μl) was collected from the tail by a small incision. Serum creatinine (SCr) was measured using a creatinine reagent assay (Raichem, San Marcos, Calif., USA) according to the manufacturer's protocol. Briefly, 20 μl of serum was mixed with 200 μl of working reagent at 37 ° C in a 96-well plate, and the absorbance was read at 510 nm at 40 and 100 s using a Molecular Devices Versa Max plate reader (Molecular Devices, Sunnyvale, Calif., USA). Hemoglobin was measured using a Hemoglobin Assay Kit (Sigma-Aldrich, St. Louis, Mo., USA) according to the manufacturer's protocol. Briefly, 50 μl of plasma was transferred into a well along with 200 μl of reagent. A calibrator and blank were run each time. The samples were then incubated for 5 min at room temperature before measuring the absorbance at 400 nm using the end point method (Softmax Pro 6.1) on the Molecular Devices Versa Max plate reader (Molecular Devices, Sunnyvale, Calif., USA). Calculations were made comparing the plasma sample minus the blank, against the calibrator minus the blank.
Prothrombin time (PT) was measured using an Electra 750 coagulation analyzer (Medical Laboratory Automation, Pleasantville, N.Y., USA) according to the manufacturer's protocol. Briefly, blood was collected into tubes containing 3.8% sodium citrate as the anticoagulant in a ratio of 9: 1. The blood was centrifuged at 1,000 RCF for 15 min. Then, 0.1 ml of serum was placed in the incubation station for 3 min and 0.2 ml of warm thromboplastin was added. The pipette plunger was pushed down as the test was started. Clotting time was recorded. We used a 'surrogate' international normalized ratio (sINR) by comparing PT after and before the treatment, as described previously [9, 11] . The average PT from 100 untreated rats was used as the normal PT time (20.7 s).
Renal morphology was evaluated by 2 independent renal pathologists blinded to the experimental group. Kidneys were cut at the longitudinal axis; a half of each kidney was embedded in paraffin after fixation in 10% buffered formalin for 24 h. Three micrometer sections were stained with hematoxylin and eosin. Immunohistochemical analysis was performed on sections of paraffin-embedded tissue after antigen retrieval, according to the manufacturer's protocol. Anti-CD31 antibodies (BD Bioscience, San Jose, Calif., USA) were used for endothelial cell staining.
Statistical Analysis
Results are presented as mean ± standard deviation if not otherwise specified. Differences between groups were analyzed by the two-paired t test or analysis of variance (ANOVA) 
Results
BDF Induces Hemoglobinuria Early after Administration
After a single gavage with BDF, animals developed early hemoglobinuria/hematuria, which was detected by a DiaScreen reagent strip (dipstick). This BDF-induced hematuria/hemoglobinuria was evident at 30 min and showed dose-dependency on the amount of BDF administered ( fig. 1 a) . Based on the manufacturer's data, this test is positive for both hematuria and hemoglobinuria. Therefore, we performed a microscopic analysis of the urine sediment and did not find any red blood cells (RBCs) in the samples. This suggests that BDF induces rapid hemoglobinuria, and not hematuria.
Next, we analyzed blood samples collected at 30 min, 2 and 24 h after BDF treatment. There was an initial temporal decrease in hematocrit after BDF administration ( fig. 1 b) . Thus, 30 min after administration of 0.4 mg/kg BDF, hematocrit decreased from 37.14 ± 3.77 to 33.33 ± 5.69% (p = 0.0211). After 2 hours, hematocrit was still low (32.86 ± 6.21%, p = 0.0158 as compared to baseline), but it recovered 24 h after administration of 0.4 mg/kg BDF (41.80 ± 1.75%, p = 0.009, as compared to baseline). Treatment with a higher dose of BDF (1.0 mg/kg) resulted in a greater decrease in hematocrit at 30 min after BDF Fig. 1 . Early BDF effects on urinalysis and hematocrit. The following number of animals was treated with BDF: 0.4 mg/kg, n = 16; 1.0 mg/kg, n = 6. Vehicle-treated rats (n = 15) received the same volume of solvent. a A single dose of BDF was administered via oral gavage to rats in the doses shown. Urine was probed with a DiaScreen reagent strip (dipstick) at 30 min and hourly thereafter up to 4 h after BDF administration. Results were graded using a semi-quantitative scale of 0-3+. Score 0 was designated for no hematuria, score 1+ for mild hematuria, score 2+ for moderate hematuria and score 3+ for severe hematuria. b Hematocrit was determined in the blood samples at 30 min, 2 and 4 h after BDF treatment. c Free hemoglobin was measured in the serum using the Hemoglobin Assay Kit. d Gross appearance of blood samples after 0.4 mg/kg (rat 1) and 1.0 mg/kg (rat 2) BDF treatment. Gross hemolysis was evident at 30 min and 2 h after BDF administration. fig. 1 b) , but this also recovered at 24 h after administration (38.00 ± 3.58%, p = 0.4474 as compared to baseline). Grossly, we observed hemolysis in blood samples collected at 30 min after BDF, but not at 2 or 24 h ( fig. 1 d) . Measurement of free hemoglobin in the serum showed a dosedependent increase which lasted for at least 2 h after BDF treatment, but was normalized 24 h after administration ( fig. 1 c) . These results suggest that that the substance detected by the reagent strip in hematuric/hemoglobinuric urine is hemoglobin, which was consistent with absence of RBCs in the urine. We attempted to measure free hemoglobin in the urine using the same Hemoglobin Assay
Kit, but because this kit is pH sensitive, our results were inconclusive. Because of the small volume of urine collected, we were not able to normalize pH in the samples.
Late Renal Effects of BDF Are Associated with Anticoagulation
The primary action of BDF is anticoagulation. Consistent with this, the PT was significantly and rapidly increased after BDF administration in a dose-dependent manner ( fig. 2 a) . Thus, sINR was increased to 2.27 ± 0.58 and 3.31 ± 0.24 at day 3 after 0.4 mg/kg and 1.0 mg/kg of BDF, respectively (we were able to collect tail blood with- out risk of significant bleeding up to day 3 after BDF administration). Simultaneously, there was an increase in hematuria/hemoglobinuria detected by dipsticks, which also was BDF dose-dependent ( fig. 2 b) . Microscopy of the urine sediment showed RBCs in the urine, including acanthocytes, indicating true glomerular hematuria ( fig. 2 c) . Histological evaluation of kidney sections did not show significant pathologic changes, similar to our data with uncontrolled BDF poisoning [9] . There was mild acute tubular injury in proximal tubular epithelial cells with focal loss of brash border and mild vacuolization of proximal tubular epithelial cells ( fig. 2 c) . No tubular or Bowmen's space RBCs were seen. A single RBC tubular cast was seen in an animal treated with 1 mg/kg BDF ( fig. 2 c) . No RBC tubular casts were seen in any of other kidneys obtained from 22 animals treated with BDF. Immunohistochemical analysis with an antibody to CD31 was performed, highlighting the similar number of capillaries and the pattern in the peritubular capillaries and vasa recta distribution in both BDF and vehicle-treated rats (data not shown). SCr levels were increased after BDF treatment in a dose-dependent manner ( fig. 2 d) . However, those changes were not statistically significant between groups (ANOVA, p = 0.2820), which corresponds to our previous data where animals had free access to BDF in pellets [9] . No significant changes in SCr were observed in samples collected at 30 min or 2 h after BDF administration (data not shown).
NAC Prevents Early Hemoglobinuria but Does Not Affect Late Hematuria
Based on our data that warfarin induces oxidative stress in the rat kidney [8] , we tested the hypothesis that early BDF-associated hemoglobinuria could be due to oxidative stress. To test this, rats were given NAC per os in drinking water 24 h prior to the BDF administration. NAC decreased early hemoglobinuria associated with 0.4 mg/kg BDF in a dose-dependent manner. Pre-treatment with 10 mg/kg/day NAC partially decreased hemoglobinuria, whereas 100 mg/kg/day NAC completely prevented BDF-induced hemoglobinuria ( fig. 3 a) . The decrease in hemoglobinuria was associated with a decrease in gross hemolysis and lesser changes in hematocrit associated with BDF poisoning ( fig. 3 b) . In contrast, pre-treatment with NAC did not affect late hematuria caused by 0.4 mg/kg BDF at either dose ( fig. 3 c) . Similarly, the BDF anticoagulation was not affected by NAC (data not shown), similarly to effects of NAC on warfarin anticoagulation [12] .
Discussion
To the best of our knowledge, this is the first and only report that describes early renal effects of BDF. We demonstrated that BDF has dual action on the kidney: (1) it results in early transient hemoglobinuria and (2) it induces true glomerular hematuria, which is associated with anticoagulation. These early and late BDF effects on the kidney were dose-dependent. The late hematuria in experimental animals was demonstrated earlier by our group in rats who had free access to BDF in pellets ('uncontrolled' BDF) [9] . Patients with BDF intoxication also present with hematuria which is associated with coagulopathy [13, 14] . However, the early transient hemoglobinuria is a novel finding, which may be a useful biomarker of BDF poisoning.
Based on our data, we propose that early effects of BDF are mediated via oxidative stress resulting in hemolysis, as is evident by gross hemolysis and decreased hematocrit after BDF administration. Indeed, earlier, we demonstrated increased oxidative stress in the kidneys in warfarin-treated rats [12] . It is likely that BDF also induces oxidative stress; such an effect is supported by our data showing that pre-treatment with NAC prevents BDF-induced early hemoglobinuria ( fig. 3 ) . The source of this oxidative stress is not yet known. One possibility is that oxidative stress is mediated by the bromine atom present in BDF. It is well known that bromobenzene is a potent mitochondrial inhibitor [15, 16] ; therefore, the bromobenzene moiety in BDF may exert similar effects. It is also possibly that the bromine group is ionized to a bromide ion that is released after the BDF absorption in the gastrointestinal tract ( fig. 4 ) , after that a conversion of bromide ion to nitrous bromide or hypobromous acid can occur, which is known to affect mitochondrial functions, resulting in increased oxidative stress [17] . It has been demonstrated that warfarin interacts with polymorphonuclear leukocyte myeloperoxidase [18] , which may induce hemolysis. It is possible that BDF also may interact with polymorphonuclear leukocytes and thereby also induce rapid temporal hemolysis. Finally, the strong hydrophobic nature of BDF (its log p value, a measure of relative solubility in octanol vs. water, is 8.2, almost 5 orders of magnitude greater than that of warfarin, which is 2.8) raises the possibility that BDF directly interacts with cell membranes (either endothelial or hepatocytes), leading to cell damage. The BDF-induced hemolysis is rapid and temporal, as it is evident by rapid recovery of hematocrit within 24 h after the BDF treatment. Such rapid recovery of hematocrit is probably related to a large regenerative capacity of the bone marrow and influx of RBCs from the extravascular storage [19] [20] [21] .
In contrast to rapid actions, the delayed effects of BDF are more likely related to the vitamin K depletion and resulting excessive anticoagulation ( fig. 4 ) [9] . As the case for warfarin [11] , these effects are probably mediated through decreased thrombin activity, increased oxidative stress and endothelial cell injury with the consequent damage of the vascular barrier in multiple organs, including the kidney [9] .
Based on this pathogenesis of BDF actions, we propose that early hemoglobinuria and delayed hematuria are novel biomarkers of BDF exposure and toxicity. Specifically, early transient hemoglobinuria indicates BDF ingestion, whereas late hematuria indicates BDF-induced coagulopathy. These can be used as monitoring and treatment biomarkers in the case of incidental BDF ingestion or mass casualty associated with BDF poisoning ( fig. 5 ) . Monitoring of hematuria/hemoglobinuria is relatively simple, can be easily achieved in the outpatient setting; therefore, useful in a mass casualty scenario. We propose that after possible BDF ingestion, patients should be tested as soon as possible for hematuria (hemoglobinuria) by a dipstick (within the first 4-12 h). Those who are positive should be retested again in 6-8 h. If the hematuria (hemoglobinuria) becomes negative, it is indicative of BDF poisoning (early transient hemoglobinuria as the biomarker). These patients should be monitored for coagu- lopathy and treated, if needed. The main pathogenic mechanism of BDF is the depletion of bioavailable vitamin K. Therefore, it is imperative to supplement vitamin K in patients with BDF poisoning. We believe that cotreatment with vitamin K and NAC will be beneficial, because vitamin K by itself may induce endothelial cell dysfunction via oxidative stress [22] . Importantly, NAC does not affect the late hematuria associated with BDF anticoagulation; therefore, early NAC administration will not mask hematuria in BDF poisoned patients ( fig. 3 c) [12] . Those who have persistent, but not increasing hematuria after 6-8 h of the initial testing likely have an underlying condition causing hematuria or BDF poisoning that occurred more than 24-48 prior. These patients should be checked for coagulation (PT) in order to exclude BDFassociated late hematuria, and, if PT is normal, can be In patients who survived, long-term BDF effects lead to endothelial cell injury, chronic anticoagulation and damage of the vascular barrier in multiple organs. MGP = Matrix glutamate protein; GAS-6 = growth arrest-specific gene 6. discharged with dipsticks provided to monitor daily hematuria for a week. For people with suspected BDF intoxication and with negative initial hematuria, the differential diagnosis includes the following: (1) no BDF exposure or (2) the test was performed too late, after hemoglobinuria spontaneously resolved. These patients may be released, but they should be provided with dipsticks and tested for hematuria daily. As an increase in hematuria is indicative of BDF poisoning, the patients who develop hematuria within a week after possible BDF poisoning should be immediately transferred to a medical facility, INR determined and treatment begun ( fig. 5 ) . Finally, our studies have only tested acute effects of BDF; however, several other superwarfarins are currently in use as rodenticides, and it is possible that the same rapid transient hemoglobinuria will occur following ingestion of those compounds as well.
In conclusion, we present evidences that BDF has dual action on the kidney, resulting in hemolysis and consecutive hemoglobinuria early after administration. These effects are transient and diminish or disappear within 24 h after BDF poisoning. Late effects of BDF are anticoagulation related and include true glomerular hematuria with RBCs and dysmorphic RBCs in the urine. These novel biomarkers of BDF poisoning are potential biomarkers for the identification and triage of accidental or intentional BDF ingestion.
